This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pradines, B.
Right arrow Articles by Rogier, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pradines, B.
Right arrow Articles by Rogier, C.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, July 2006, p. 2404-2408, Vol. 44, No. 7
0095-1137/06/$08.00+0     doi:10.1128/JCM.00623-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Prevalence of In Vitro Resistance to Eleven Standard or New Antimalarial Drugs among Plasmodium falciparum Isolates from Pointe-Noire, Republic of the Congo

Bruno Pradines,1,2* Philippe Hovette,3 Thierry Fusai,1,2 Henri Léonard Atanda,3 Eric Baret,1,2 Philippe Cheval,3 Joel Mosnier,1,2 Alain Callec,3 Julien Cren,4,2 Rémy Amalvict,1,2 Jean Pierre Gardair,5 and Christophe Rogier1,2

Unité de Recherche en Biologie et Epidémiologie Parasitaires, Institut de Médecine Tropicale du Service de Santé des Armées, Le Pharo, 13998 Marseille, France,1 Institut Fédératif de la Recherche no. 48, 13385 Marseille, France,2 Centre Médical de Secours, Total Exploration et Production Congo, Pointe-Noire, Republic of the Congo,3 Unité de Recherche en Physiologie et Pharmacocinétique Parasitaires, Institut de Médecine Tropicale du Service de Santé des Armées, Le Pharo, 13998 Marseille, France,4 Département Médical International, Total, 92078 Paris la Défense, France5

Received 23 March 2006/ Accepted 11 May 2006

We determined the level of in vitro resistance of Plasmodium falciparum parasites to standard antimalarial drugs, such as chloroquine, quinine, amodiaquine, halofantrine, mefloquine, cycloguanil, and pyrimethamine, and to new compounds, such as dihydroartemisinin, doxycycline, atovaquone, and lumefantrine. The in vitro resistance to chloroquine reached 75.5%. Twenty-eight percent of the isolates were intermediate or had reduced susceptibility to quinine. Seventy-six percent and 96% of the tested isolates showed in vitro resistance or intermediate susceptibilities to cycloguanil and pyrimethamine, respectively. Only 2% of the parasites demonstrated in vitro resistance to monodesethylamodiaquine. No resistance was shown with halofantrine, lumefantrine, dihydroartemisinin, or atovaquone. Halofantrine, mefloquine, and lumefantrine demonstrated high correlation. No cross-resistance was identified between responses to monodesethyl-amodiaquine, dihydroartemisinin, atovaquone, and cycloguanil. Since the level of chloroquine resistance in vitro exceed an unacceptable upper limit, high rates of in vitro resistance to pyrimethamine and cycloguanil and diminution of the susceptibility to quinine, antimalarial drugs used in combination, such as amodiaquine, artemisinin derivatives, mefloquine, lumefantrine, or atovaquone, seem to be appropriate alternatives for the first line of treatment of acute, uncomplicated P. falciparum malaria.

* Corresponding author. Mailing address: IMTSSA, URBEP, Bd. C. Livon, Parc le Pharo, BP 46, 13998 Marseille Armées, France. Phone: 33 4 91 15 01 10. Fax: 33 4 91 15 01 64. E-mail: bruno.pradines{at}free.fr.

Journal of Clinical Microbiology, July 2006, p. 2404-2408, Vol. 44, No. 7
0095-1137/06/$08.00+0     doi:10.1128/JCM.00623-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Mwai, L., Kiara, S. M., Abdirahman, A., Pole, L., Rippert, A., Diriye, A., Bull, P., Marsh, K., Borrmann, S., Nzila, A. (2009). In Vitro Activities of Piperaquine, Lumefantrine, and Dihydroartemisinin in Kenyan Plasmodium falciparum Isolates and Polymorphisms in pfcrt and pfmdr1. Antimicrob. Agents Chemother. 53: 5069-5073 [Abstract] [Full Text]  
  • Reyburn, H., Mtove, G., Hendriksen, I., Seidlein, L. v. (2009). Oral quinine for the treatment of uncomplicated malaria. BMJ 339: b2066-b2066 [Full Text]  
  • Achan, J., Tibenderana, J. K, Kyabayinze, D., Wabwire Mangen, F., Kamya, M. R, Dorsey, G., D'Alessandro, U., Rosenthal, P. J, Talisuna, A. O (2009). Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ 339: b2763-b2763 [Abstract] [Full Text]  
  • Briolant, S., Baragatti, M., Parola, P., Simon, F., Tall, A., Sokhna, C., Hovette, P., Mamfoumbi, M. M., Koeck, J.-L., Delmont, J., Spiegel, A., Castello, J., Gardair, J. P., Trape, J. F., Kombila, M., Minodier, P., Fusai, T., Rogier, C., Pradines, B. (2009). Multinormal In Vitro Distribution Model Suitable for the Distribution of Plasmodium falciparum Chemosusceptibility to Doxycycline. Antimicrob. Agents Chemother. 53: 688-695 [Abstract] [Full Text]  
  • Parola, P., Pradines, B., Simon, F., Carlotti, M.-P., Minodier, P., Ranjeva, M.-P., Badiaga, S., Bertaux, L., Delmont, J., Morillon, M., Silai, R., Brouqui, P., Parzy, D. (2007). Antimalarial Drug Susceptibility and Point Mutations Associated with Drug Resistance in 248 Plasmodium falciparum Isolates Imported from Comoros to Marseille, France in 2004 2006. Am J Trop Med Hyg 77: 431-437 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»